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Abstract
Adenocarcinoma (AdC) is the most common lung cancer subtype and is often associated
with pleural effusion (PE). Its poor prognosis is attributable to diagnostic delay and lack of
effective treatments and there is a pressing need in discovering new biomarkers for early
diagnosis or targeted therapies. To date, little is known about lung AdC proteome. We in-
vestigated protein expression of lung AdC in PE using the isobaric Tags for Relative and
Absolute Quantification (iTRAQ) approach to identify possible novel diagnostic/prognostic
biomarkers. This provided the identification of 109 of lung AdC-related proteins. We further
analyzed lumican, one of the overexpressed proteins, in 88 resected lung AdCs and in 23
malignant PE cell-blocks (13 lung AdCs and 10 non-lung cancers) using immunohistochem-
istry. In AdC surgical samples, lumican expression was low in cancer cells, whereas it was
strong and diffuse in the stroma surrounding the tumor. However, lumican expression was
not associated with tumor grade, stage, and vascular/pleural invasion. None of the lung can-
cer cell-blocks showed lumican immunoreaction, whereas those of all the other tumors
were strongly positive. Finally, immunoblotting analysis showed lumican expression in both
cell lysate and conditioned medium of a fibroblast culture but not in those of A549 lung can-
cer cell line. PE is a valid source of information for proteomic analysis without many of the
restrictions of plasma. The high lumican levels characterizing AdC PEs are probably due to
its release by the fibroblasts surrounding the tumor. Despite the role of lumican in lung AdC
is still elusive, it could be of diagnostic value.
Introduction
Lung cancer is the leading tumor worldwide for incidence and mortality and is classified ac-
cording to histological type into two broad classes: the small-cell lung carcinoma and the more
common non-small-cell lung carcinoma, further divided in adenocarcinoma (AdC), squamous
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cell carcinoma, and large cell carcinoma [1,2]. AdC alone accounts for about 40% of all lung
cancers, it is usually located in periphery of the lung and may present with a pleural effusion
(PE). Despite the recent advances in lung cancer treatment, prognosis is still poor, mainly be-
cause of diagnostic delay. Thus, it is crucial to identify new biomarkers involved in the molecu-
lar mechanisms underlying tumor genesis and progression, which could be useful for early
detection or for the development of novel therapeutic strategies.
Proteomics provides an unbiased opportunity to discover new potential pathogenic mecha-
nisms and therapeutic targets, as well as biomarkers of disease [3]. Such approaches are gener-
ally applied to a small cohort of patients to generate hypotheses that need to be validated in
larger cohorts [4]. To date, proteomics has been rarely exploited to discover new aspects of
AdC and the findings have never been properly validated [5]. The use of high-throughput tech-
nologies, such as shotgun proteomics, which combines liquid chromatography (LC) with mass
spectrometry (MS), allows the identification and quantification of a large number of proteins
even from small specimens (both solid tissue and liquid material). However, validation of the
altered expression of such a large amount of proteins in biologic processes and in diseases is
often difficult. Plasma is one of the most common body fluids used for the identification and
validation of novel biomarkers of disease. To date, the plasma proteome associated with many
diseases has been intensively investigated, although it is analytically challenging [6,7]. Indeed,
the ten most abundant plasma proteins account for approximately 90% of the total protein
content, whereas other proteins are present in a very wide dynamic range, spanning more than
10 orders of magnitude in terms of concentration [8]. Thus, the complexity of the plasma pro-
teome exceeds the current analytical capacity of conventional approaches to isolate low abun-
dance proteins that might be informative biomarkers. Malignant PE, instead, seems to be a
valid alternative source for biomarker discovery. Indeed, the prolonged cancer cell growth in
the closed pleural cavity concentrates the secreted proteins clearing many of technical chal-
lenges associated with the plasma proteome analysis; the emphasis is shifting from cancer cells
to the non-cellular portion of PE.
In this study, we first used the isobaric Tags for Relative and Absolute Quantification
(iTRAQ) approach as a gold-standard proteomic strategy to compare proteins present in PE of
patients with and without AdC. Then we selected lumican as candidate target to be further vali-
dated in a series of surgical and cytological AdC samples.
Materials and Methods
Materials
This study was approved (No. 46728) by the Institutional Ethical Review Board of Padua Uni-
versity that waived the need for consent. The institute’s ethical regulations on research con-
ducted on human tissues were followed. All fresh PE submitted for routine diagnostic
evaluation to our Cytopathology Unit during 2010 were immediately centrifuged for 20 min-
utes at 2,000 x g to separate the cells from the supernatant fluid on their arrival at the laborato-
ry. Cells were then processed to prepare the cytological smears, whereas the supernatant fluid
was centrifuged again at 2,000 x g for 30 minutes to remove cellular debris and contaminants.
Then, 10 ml of the fluid were transferred to a new container without disturbing the pellet and a
tablet of cOmplete, Mini, EDTA-free protease inhibitor (Roche, Mannheim, Germany) was
added. The mixture was gently shaken until complete dissolution of the tablet and readily
stored at -80°C until further use. Among all these samples, we selected three PEs positive for
AdC malignant cells at the cytological examination. All were obtained before the administra-
tion of chemotherapy and surgical treatment to the patients and were histologically confirmed.
As controls, three PEs obtained from patients affected by congestive heart failure were also
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included; these samples were proven to be transudates according to Light’s criteria and were
cytologically negative for neoplastic cells [9].
From the archives of the Surgical Pathology and Cytopathology Unit of the University of
Padua for the period between 2010 and 2011, we retrieved the resected specimens of 88 lung
AdCs (clinical and pathological data for these cases are reported in Table 1) and 5 normal lung
tissue from distant areas in cancer pneumonectomies. In addition, 10 lung AdC, 3 NSCLC-not
otherwise specified (NOS), 5 ductal breast carcinoma (no special type), and 5 serous ovarian
carcinoma cell-blocks were also included. All the cases were reviewed and the diagnoses con-
firmed in all instances by 2 pathologists (AF and RC) according to the World Health Organiza-
tion classification [2].
Sample preparation for proteomic analysis
A small aliquot from each sample was diluted 10 times with MilliQ grade water for proteins
quantification using microBCA (Thermo Fisher Scientific, Somerset, USA) method. Two pools
were obtained by mixing equal quantities of proteins from AdC and non-neoplastic PE sam-
ples. Proteins (200 μg) from each pool were precipitated overnight at -20°C with four volumes
of cold acetone. Protein pellets were dissolved in 5 ml of 50 mM ammonium bicarbonate, 0.1%
Triton X-100 and sonicated on ice. Samples were centrifuged at 14,000 x g for 10 minutes at
4°C to remove insoluble debris. The supernatants were concentrated on 3 kDa molecular
weight cut-off filters (Centricon Centrifugal Filter Devices with YM-3 membranes; EMDMilli-
pore Corporation, Billerica, USA) followed by buffer exchange with 50 mM triethyl ammoni-
um bicarbonate (TEAB). Protein content from each sample was quantified again using
microBCA (Thermo Fisher Scientific) method.
Table 1. Clinicopathological features of the lung adenocarcinoma series.
Variables Numbers of patients %
Gender
Male 61 63.3
Female 27 36.7
Vascular invasion
Present 40 45.5
Absent 48 54.5
Pleural invasion
Present 32 36.4
Absent 56 63.6
Grade
1 14 15.9
2 39 44.3
3 35 39.8
TNM stage
I 25 28.4
II 25 28.4
III 26 29.5
IV 12 13.7
Patients classiﬁcation according to gender, vascular/pleural invasion, grading and staging.
doi:10.1371/journal.pone.0126458.t001
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iTRAQ labeling
Proteins (100 μg) from each pool were diluted in iTRAQ dissolution buffer (TEAB 0.5 M) to a
final volume of 100 μl. Samples were reduced, alkylated, and trypsin digested according to the
iTRAQ kit manufacturer’s instructions. After digestion, 1 μg of each sample was used to con-
firm the digestion efficiency by LC-MS/MS. To reduce any potential variation introduced by
the labeling reaction, each sample was split in two identical aliquots of 50 μg to perform two
technical replicates with tag swapping. The labeling procedure was performed following the
manufacturer’s protocol. To check the completeness of the labeling, 1 μg of each labeled sample
was individually analyzed by LC-MS/MS. Acquired data were searched with Sequest search en-
gine, setting the iTRAQ labeling as variable modification. Details about MS and data analyses
are reported below. No unmodified peptides were identified and all peptides were correctly
modified at the N-terminus and at each Lysine residue. Following iTRAQ labeling, the samples
were pooled into one clean tube and vacuum concentrated in a SpeedVac system.
Strong Cation Exchange Chromatography
The dried iTRAQ labeled sample was dissolved in 400 μl of an equilibration buffer composed
by 5 mM KH2PO4, 25% acetonitrile, pH 2.9 (adjusting the pH with 1 M H3PO4). Strong cation
exchange (SCX) was performed using a SCX cartridge (AB Sciex, Toronto, Canada). Elution
of peptides was carried out in a step-wise manner, with 500 μl of the following concentrations
of KCl in equilibration buffer: 50, 100, 150, 200, 350 mM. Each SCX fraction was then dried
under vacuum, dissolved in 500 μl of 0.1% formic acid, and desalted using Sep-Pak C18 car-
tridges (Waters Associates, Milford, USA) according to the manufacturer’s instructions.
Samples were finally dried under vacuum and stored at -20°C until the MS analyses were
performed.
Offgel fractionation
Peptides from iTRAQ pools were desalted using Sep-Pak C18 columns, eluted with 60% ACN
and dried in a SpeedVac system. Focusing was performed on Agilent 3100 Offgel Fractionator
(Agilent Technologies, Palo Alto, USA) according to the manufacturer’s protocol. After 1 h of
rehydration with a voltage of 500 V, peptides were focused until 80 kVh was reached on 24 cm
IPG strip (GE Healthcare, Milwaukee, USA) with a 4–7 pH range. The 24-well tray was used
and the collected fractions were cleaned with Sep-Pak C18 columns, dried with a SpeedVac sys-
tem and stored at -20°C until the MS analyses were performed.
nLC-ESI-MS/MS Analyses
LC-MS/MS analyses were performed on a LTQ-Orbitrap XL mass spectrometer (Thermo Fish-
er Scientific) coupled online with a nano-HPLC Ultimate 3000 (Dionex, Sunnyvale, USA—
Thermo Fisher Scientific). Samples from each SCX and IEF fraction were dissolved in 0.1% for-
mic acid, obtaining a final concentration of about 1 μg/μl. To check the completeness of peptide
labeling and for the analysis of the iTRAQ pools, 1 μg of each iTRAQ labeled sample before
fractionation and of each SCX and IEF fraction was loaded onto a homemade 10 cm chro-
matographic column packed into a pico-frit (75 μm I.D., 10 μm tip, New Objectives) with C18
material (ReproSil, 300Å, 3 μm). Peptides were eluted with a linear gradient of acetonitrile/
0.1% formic acid from 3% to 50% in 90 min at a flow rate of 250 nl/min. The instrument was
programmed to perform a full scan at high resolution on the Orbitrap, followed by MS/MS
scans on the three most intense ions acquired with CID fragmentation in the linear ion trap.
On the same ions, a further HCD fragmentation was performed with detection on the Orbitrap,
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to record the low molecular weight ions necessary for the quantification [10]. To improve pro-
tein identification and quantification, data were searched with Mascot (as specified below) and
all peptides identified with high or medium confidence were inserted into a static exclusion
list. All samples were analyzed again under the same instrumental and chromatographic
conditions.
MS data analysis
Raw files from Orbitrap instrument were analyzed using Proteome Discoverer 1.2 (Thermo
Fisher Scientific) connected to a Mascot server (Matrix Science, London, UK) and to Sequest
Search Engine (Thermo Fisher Sicentific). Search was done against the human section of the
Uniprot database (version 2012/07/26). Peptide tolerance was set to 10 ppm for MS spectra,
fragment tolerance was set to 0.6 Da for MS/MS spectra. Enzyme specificity was set to Trypsin
with up to 1 missed cleavage. Methyltiocysteine, 4-plex iTRAQ at N-terminus and Lys were set
as fixed modifications and oxidation of methionine was selected as variable modification. False
discovery rates (FDR) of 5% and 1% were calculated by Proteome Discoverer based on the
search against the corresponding randomized database.
Results obtained from every LC-MS/MS analysis (from each SCX fraction, before and after
the application of the static excluding list), were merged by Proteome Discoverer into a single
file. A single list of globally identified proteins was obtained and peptides that could not be un-
equivocally attributed to a single protein were grouped into protein families to satisfy the prin-
ciple of maximum parsimony. Data were filtered considering as positive hits all proteins
identified with at least two unique peptides with medium confidence (FDR 5%) and quantified
with at least 2 independent peptides.
Data obtained from the IEF fractionation were further elaborated. Theoretical values of pI
peptides belonging to the same IEF fraction were calculated in batch using the “pI Calculator”
software [11]. As explained elsewhere, we took advantage of the pI filtering application to opti-
mize the cross correlation parameter (Xcorr) to assess the performance of different SEQUEST
settings and consequently to select the best setting to use [7]. Using this approach, the best val-
ues for Xcorr were the following: Xcorr1.7 for +2 tryptic peptides,2.5 for +3 and +4 tryptic
peptides for medium confidence identifications, Xcorr1.6 for +2 tryptic peptides,2.2 for
+3 and +4 tryptic peptides for high confidence identifications. A ratio1.5 or 0.66 among
AdC and non-neoplastic PE samples was set as threshold for protein over-expression and
under-expression, respectively.
Immunohistochemistry
Immunohistochemistry was performed on 4–5 μm-thick formalin-fixed and paraffin-embed-
ded (FFPE) sections from each tissue sample and cell-block. Staining was done automatically
(BondmaX, Menarini, Florence, Italy), as described elsewhere [12,13], using the Bond Polymer
Refine Detection kit (Leica Microsystem, Wetzlar, Germany), with anti-lumican antibody
(polyclonal; Novus Biologicals, Littleton, USA; working dilution 1:100, 25 min, citrate buffer).
Sections were then slightly counterstained with hematoxylin. Normal prostate sections were
used as positive controls, whereas sections processed without primary antibody as negative
ones. Lumican expression was jointly evaluated by two pathologists (R.C. and A.F.) unaware of
any clinical information. Lumican expression was first assessed in normal lung tissue to under-
stand its usual localization and intensity. Then it was semi-quantitatively scored on the base of
the percentage of AdC cells with cytoplasmic immunoreation: 0 = no stain, 1 = 1–30%, 2 = 31–
70%, and 3 = 71–100%. Finally, the area of stromal/extracellular lumican immunostaining was
measured by superimposing a grid and counting the points intercepting the positive and
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negative zones as previously described [14]. The proportion of positive stromal/extracellular
area was calculated, recorded as percentage, and classified as absent (<5%), low (5–50%), and
high (>50%) expression.
Cell lines
A549 lung cancer cells were purchased from the American Type Culture Collection (ATCC,
Manassas, USA) and maintained in DMEM/F12 medium supplemented with 10% FBS and 1%
antibiotic/antimycotic mixture. Fibroblasts were obtained from skin biopsies, as described else-
where [15], and were cultured in HAM'S F-10 (Sigma-Aldrich, St. Louis, USA) supplemented
with 10% FBS, 1 mmol/l glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin at 37°C
until confluence. A549 cells and fibroblasts were cultured with serum-free medium for 24 h
and then the quiescent medium was changed with DMEM supplemented with 1% Nutridoma
mixture (Roche) for 48h before protein extraction.
Immunoblotting
Cell pellets were homogenized in 300 μl M-PER Mammalian Protein extraction buffer
(Thermo Scientific) using a MagNALyser Instrument (Roche). Culture medium (30 ml) from
each cell line was collected, centrifuged for 30 min at 2,000 x g to pellet cell debris, and the pro-
teins secreted in the supernatant were concentrated by acetone precipitation to 500 μl. Protein
concentration was determined with microBCA (Thermo Scientific) method, using bovine
serum albumin standard. Cleared protein lysates from the cell lines and the concentrated cul-
ture medium were separated on 10% SDS-PAGE gel and electro-transferred onto nitrocellulose
membranes (Hybond ECL Amersham Biosciences, Glattbrugg, Switzerland). The membranes
were blocked for 2 hrs using 5% BSA in 1X TBS and then incubated overnight with anti-lumi-
can antibody (1:500 in dilution; Novus Biologicals). The immunoblotted proteins were incu-
bated with horseradish proxidase-conjugated secondary antibodies (DAKO, Milan, IT) and
visualized by a luminol-based chemiluminescence substrate (LumiGLO; KPL, Gaithersburg,
USA). Images were processed by Molecular imager VersaDoc system (Biorad, Milan, Italy).
The membranes were washed and reblotted with an anti GAPDH antibody used as positive
control for intracellular proteins from A549 cancer cells and fibroblasts (Cell Signaling, Dan-
vers, USA). All reactions were performed in triplicate.
Statistical analysis
Correlations among IHC results and clinicopathological variables were analyzed by using the
Kruskal-Wallis test and Wilcoxon rank sum test, as appropriate. A p-value<0.05 was consid-
ered statistically significant, while values in the range of 0.10 p0.05 were assumed to indi-
cate a statistical trend. All statistical analyses were performed using the R software (R
Development Core Team, version 2.9; R Foundation for Statistical Computing, Vienna, Aus-
tria; www.R-project.org).
Results
Proteomic of pleural effusions
Overall, 109 protein groups were identified in both AdC and non-neoplastic PE samples (full
list provided in S1 Table). Thirty proteins, mainly inflammatory or immune-related, were dif-
ferentially expressed with an increased/decreased expression of at least 50% in AdC compared
to non-neoplastic PE (Table 2). A protein overexpressed in neoplastic PE samples was selected
for further validation: lumican. Lumican is a member of the small leucine-rich proteoglycan
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(SLRP) family involved in several cellular functions, including cell proliferation, migration, and
differentiation [16–18].
Table 2. Proteomic analysis results.
Protein Symbol Ratio
Overexpressed
G-protein coupled receptor 98 GPR98 2.546
N-acetylmuramoyl-L-alanine amidase PGLYRP2 2.046
Monocyte differentiation antigen CD14 CD14 1.696
Complement component C7 C7 1.650
Isoform 2 of Sex hormone-binding globulin SHBG 1.613
Ig gamma-2 chain C region IGHG2 1.613
Alpha-2-HS-glycoprotein AHSG 1.567
Retinol-binding protein 4 RBP4 1.544
Lumican LUM 1.507
Underexpressed
Protein S100-A8 S100A8 0.077
Isoform 2 of Rho GTPase-activating protein 25 ARHGAP25 0.131
Protein S100-A9 S100A9 0.155
Neutrophil defensin 1 DEFA1 0.192
Histone H2A type 1-H HIST1H2AH 0.208
Isoform 2 of C-reactive protein CRP 0.223
Histone H4 HIST1H4A 0.283
Histone H2B type 1-H HIST1H2BH 0.283
Ig mu chain C region IGHM 0.375
Isoform 2 of Brain acid soluble protein 1 BASP1 0.419
Actin ACTB 0.444
Histone H3.3C H3F3C 0.491
Ig kappa chain V-I region EU - 0.492
Ig heavy chain V-III region TIL - 0.548
Serum amyloid A protein SAA1 0.554
Serum amyloid P-component APCS 0.564
Ig gamma-1 chain C region IGHG1 0.573
Isoform 2 of Arf-GAP with Rho-GAP domain, ANK repeat and PH domain-containing protein 1 ARAP1 0.578
Ig lambda chain V-I region WAH - 0.587
Ig lambda-2 chain C regions IGLC2 0.588
Ig kappa chain V-I region AG - 0.590
Ig heavy chain V-I region HG3 - 0.593
Ig kappa chain V-IV region Len - 0.601
Lipopolysaccharide-binding protein LBP 0.604
Ig kappa chain V-III region WOL - 0.618
Ig kappa chain V-II region TEW - 0.643
Isoform 3 of 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase eta-1 PLCH1 0.649
Ig lambda chain V-III region SH - 0.634
Ig kappa chain V-IV region JI - 0.654
Proteins with different expression between lung adenocarcinoma and non-neoplastic pleural effusions.
doi:10.1371/journal.pone.0126458.t002
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Immunohistochemistry
In normal lung tissue, lumican was expressed by both epithelial and mesenchymal cells. In-
deed, a diffuse cytoplasmic immunoreaction was detectable in type I and II pneumocytes, co-
lumnar cells of the bronchi, fibroblasts and vascular smooth muscle cells (Fig 1). Moreover,
lumican was detected in collagen fibers of the perivascular and peribronchial connective tissues
(Fig 1).
Overall, the IHC expression of lumican in the 88 resected AdCs was low. Indeed, none of
the AdCs showed a lumican immunoreaction in more than 70% of tumor cells and in only 12
cases it exceeded the 31% (Fig 2). The large majority of AdCs (69 cases) was scored as 1 (1–
30% of positive tumor cells) (Fig 1), whereas in 7 cases no immunostaining was detected (Fig
2). Any possible association of lumican IHC expression with tumor grade, stage (pTNM), and
vascular/pleural invasion (evaluated on hematoxylin & eosin stained slides) was ruled out in re-
sected AdCs. Lumican looked more expressed in the surrounding tumor stroma and extracellu-
lar space than in AdC cells and normal lung (Fig 1).
For this reason, stromal/extracellular lumican immunostaining was quantitatively measured in
the connective tissue surrounding the tumors. In all cases, a stromal/extracellular positive immu-
noreaction was detected. However, stromal/extracellular positive lumican area resulted strong,
uniform, and higher than 50% in 39 cases, whereas spanned the range of 5–50% in 32 cases. In the
remaining 17 cases, immunoreaction was scarce and scattered (Fig 2). Again, lumican immunor-
eaction was not related to tumor grade, stage (pTNM), and vascular/pleural invasion.
Fig 1. Representative images from the considered series. In normal lung (A and B), lumican
immunoreaction was detectable not only in the cytoplasm of pneumocytes, columnar cells of the bronchi,
fibroblasts (inset), and vascular smooth muscle cells, but also in collagen fibers of the perivascular and
peribronchial connective tissues. In lung adenocarcinoma (C and D), lumican immunostaining was low in
tumor cells and more diffuse in the surrounding tumor stroma and extracellular space. (Original magnification
200x in A and D, 100x in B, and 40x in C).
doi:10.1371/journal.pone.0126458.g001
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As for tumor cell-blocks, none of the 10 AdC as well as the 3 NSCLC-NOS ones showed
lumican immunoreaction (Fig 3), in accordance with the low expression detected in the re-
sected specimens. Contrariwise, the 5 breast carcinoma and 5 ovarian carcinoma specimens
were all strongly positive for lumican (Fig 3).
Immunoblotting
In order to assess the source of lumican in PEs, immunoblotting was performed both in cell ly-
sate and conditioned medium (a serum surrogate was used to avoid interferences) obtained
from an AdC cell line (A549) and a fibroblast culture. Immunoblotting analysis showed that
lumican was expressed in fibroblasts but not in AdC cells (Fig 4). As for the supernatant, lumi-
can showed an uneven band in the A549 line and was clearly detected in the fibroblast one (Fig
4). The molecular weight of lumican in fibroblasts slightly exceeded 40 kDa, whereas in the cor-
responding conditioned medium ranged from 35 kDa to more than 55 kDa.
Discussion
AdC is the most common histotype of lung cancer, the leading tumor worldwide for incidence
and mortality. Despite the recent improvements in the treatment, prognosis remains poor
Fig 2. Immunohistochemistry results.Overall, grade, stage, vascular and pleural invasion distribution of immunohistochemical staining scores for lumican
in lung adenocarcinoma (A) and in the surrounding stroma (B).
doi:10.1371/journal.pone.0126458.g002
Fig 3. Representative images from the tumor cell-blocks. Lumican immunostaining was absent in lung
adenocarcinoma cells (A), whereas it was strong and diffuse in breast carcinoma (invasive carcinoma of no
special type) cells (B). (Original magnification 400x in A and B).
doi:10.1371/journal.pone.0126458.g003
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mainly because a diagnosis is usually achieved in advanced stages, often with malignant PE. It
is estimated that about 15% of patients with lung cancer have malignant PE [19]. Since AdC
cells proliferate and secrete proteins in PE, a fluid with limited protein exchange with plasma,
this may represent an effective source to discover novel biomarkers. In this study we applied
the iTRAQ-LC-MS/MS proteomics approach to identify proteins with altered abundance in
AdC PE as compared to non-neoplastic PE. Among the wide AdC proteome identified, in the
present study we concentrated our attention on lumican and excluded by further investigations
all the inflammatory or immune-related proteins. Since several stimuli can cause the elevation
of this kind of proteins and many different diseases may share such alterations, they are hardly
Fig 4. Immunoblotting results. Immunoblotting analysis of lumican in Nutridoma and both cell lysate and
supernatant of A549 lung adenocarcinoma cell line and fibroblast culture.
doi:10.1371/journal.pone.0126458.g004
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suitable to be employed as AdC specific biomarkers. However, also these proteins are interest-
ing and deserve to be considered in future studies, as they may be useful in the prognostic strat-
ification of patients accordingly to the most recent findings [20].
Lumican is a keratin sulphate belonging to the SLRP family of extracellular matrix (ECM)
proteins and is expressed in different forms in several tissues and organs, such as cornea, bone,
cartilage, artery, skin, kidney, and lung [17,18,21]. Physiologically, lumican is involved in the
acquisition of corneal transparency, in the assembling of collagen fibrils, and in the regulation
of pivotal biological processes, mainly angiogenesis, cell proliferation, migration, and adhesion
[22–27]. These latter are important mechanisms also in cancer. Indeed, during tumor progres-
sion, cancer cells interact with the microenvironment and especially with ECM that not only
provides a physical scaffold for cell adhesion and migration but also influences tumor angio-
genesis [28,29]. Thus, alteration of lumican expression are supposed to be correlated to cancer
spreading. Indeed, lumican has been reported to regulate cell migration in prostate and colo-
rectal cancer, where is also related to a worse prognosis, and tumor progression in pancreatic
cancer [17,18]. Notably, in breast cancer high stromal lumican expression is associated with
high tumor grade and low estrogen receptor level [17,18]. Matsuda Y and colleagues studied
lumican expression in a series of adenocarcinomas and squamous cells carcinomas of the lung
by using IHC [30]. Accordingly with our findings, in the normal lung they observed lumican
immunostaining in the bronchial epithelium, in vascular smooth muscle cells, and in fibro-
blasts and collagen fibers of the perivascular and peribronchial connective tissues [30]. Howev-
er, Matsuda Y and colleagues did not detected lumican immunoreaction in the alveolar
epithelium [30], whereas we highlighted lumican expression also in pneumocytes. Such incon-
gruence may be explained by the different clones of the antibody employed. Indeed, we used a
commercial polyclonal antibody recognizing regions in wide antigen aminoacidic sequence
that may result in a broader positivity, whereas the antibody synthetized by Matsuda Y et al re-
acted against a polypeptide of only sixteen aminoacids. In their work, Matsuda Y and col-
leagues observed lumican immunostaining in both cancer cells and stromal tissues
surrounding the tumor and found that tumor size and pleural invasion correlated with the ex-
pression levels of lumican in cancer cells [30]. Thus, the low lumican immunoreaction detected
in the large majority of AdC cases in our series and the absence of any association of lumican
expression with clinico-pathological variables were unexpected. Again, the clones of antibody
may have affected the results. However, we did not assess lumican intensity but scored the per-
centage of positive tumor cells. On the other hand, the lack of lumican expression in AdC cell
blocks corroborates its substantial absence also in the primitive site. The results of lumican
IHC in AdC and non-AdC cell blocks suggest its possible utility as diagnostic biomarker and
further studies should address this eventuality. Our findings agreed with those of Matsuda Y
et al inasmuch as lumican expression was high in the stromal tissues surrounding the AdC
cells and this did not correlate with clinic-pathological factors [30].
Immunoblotting results addressed that fibroblasts, rather than tumor cells, are a putative
source for the high lumican levels recorded in AdC PEs. This finding, however, was in contrast
to the data previously reported by Matsuda and colleagues. Indeed, they detected lumican pro-
tein in both cell extract and culture medium of the two AdC cell lines analyzed [30]. Again, the
discrepancy could be due to the different antibodies utilized. Otherwise, the diverse culture
conditions (we used Nutridoma) could be the explanation. A different glycosylation or a chem-
ical digestion in culture medium could be the reason of the uneven band and the varied lumi-
can molecular weights observed. It remains to be clarified if the high levels of lumican in PE
may also due to release by the mesothelium lining the pleural cavity. Anyway, the lumican in-
crease measured in PE could be detectable also in the plasma of AdC patients and its potential
value as early diagnostic biomarker should be explored. The biological role of lumican in AdC
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is elusive and only functional studies will elucidate if it affects tumor progression. Indeed, un-
derstanding the molecular mechanisms through which AdC interacts with the microenviron-
ment could provide the basis for the development of novel therapeutic modalities.
In conclusion, the present study demonstrated that: i) lumican is overexpressed in AdC PEs;
ii) AdC cells in both resected specimens and cell blocks substantially lack lumican immunos-
taining; iii) about half of the considered AdC cases shows a strong stromal/extracellular lumi-
can immunoreaction; iv) a presumed source of the high lumican levels detected in PEs could
be represented by fibroblast. Further studies should address the diagnostic value of lumican
and investigate its role in tumor progression.
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